Cardiac-specific myosin ATPase activators represent a novel class of agents designed to improve myocardial contractility in acute heart failure.
May warrant Phase 2 trials in acute HF; leaves open any clinical role pending randomized data.
Heart failure remains a leading cause of hospitalisation and death. Treatment of acute heart failure has not improved as rapidly as treatment for chronic heart failure. There are three classes of inotropic agents that are in use at present: the catecholamines, phosphodiesterase inhibitors and calcium sensitisers. Cardiac-specific myosin ATPase activators are a novel class of agents designed to improve myocardial contractility by accelerating the productive phosphate-release step of the crossbridge cycle. This article reviews the mechanism of action of myosin ATPase activators, the results of preclinical and Phase I studies and their potential role in the management of heart failure.
No takes yet. Share an insight, caveat, or question.
Bragadeesh et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: